Rigel Pharmaceuticals Inc
RIGL· Nasdaq
RIGLRigel Pharmaceuticals Inc
Released Nov 5, 2020, after the close
10-Q filed Nov 5, 2020, 36 days after period end · 0001558370-20-012838
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Revenue | $18.39M | $20.86M | $4.87M | $900.00K |
| Net Income | -$14.17M | -$11.49M | -$23.77M | -$17.66M |
| EPS Diluted |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| -$0.08 |
| -$0.07 |
| -$0.14 |
| -$0.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
